Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives

doi:10.3748/wjg.v25.i38.5773

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 38

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16693)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

1291

WORD

351

HTML

9328

Figures (1-1)

591

Tables (1-1)

515

Sum=12076

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

566

Download

1088

Sum=1654

Publishing Process of This Article

Item

Count

Browse

1061

Download

1905

Sum=2966

Oct 14, 2019 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (78)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Oct 14, 2019; 25(38): 5773-5788
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5773

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives

Antonio Pellino, Erika Riello, Floriana Nappo, Stefano Brignola, Sabina Murgioni, Selma Ahcene Djaballah, Sara Lonardi, Vittorina Zagonel, Massimo Rugge, Fotios Loupakis, Matteo Fassan

Antonio Pellino, Erika Riello, Floriana Nappo, Sabina Murgioni, Selma Ahcene Djaballah, Sara Lonardi, Vittorina Zagonel, Fotios Loupakis, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua 35100, Italy

Antonio Pellino, Floriana Nappo, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua 35100, Italy

Erika Riello, Stefano Brignola, Massimo Rugge, Matteo Fassan, Surgical Pathology & Cytopathology Unit, Department of Medicine, University of Padua, Padua 35100, Italy

Massimo Rugge, Veneto Cancer Registry, Padua 35100, Italy

Author contributions: Pellino A, Riello and Nappo F wrote the manuscript; Brignola S, Murgioni S, Ahcene Djaballah S, Lonardi S, Zagonel V and Rugge M contributed to the writing of the manuscript; Loupakis L and Fassan M equally contributed as senior authors, designed the aim of the editorial and wrote the manuscript.

Conflict-of-interest statement: Fotios Loupakis had roles as consultant or advisor for Roche, Bayer, Amgen and Genentech. Sara Lonardi had roles as consultant or advisor for Amgen, Bayer, Merck Serono, Lilly; she received research funding from Amgen, Merck Serono and she is part of speakers bureau of Lilly, BMS. Vittorina Zagonel received honoraria and had roles as consultant or advisor for Bristol-Mayers Squibb, Bayer, Roche, Pfizer, Janssen, Novartis, Astellas, Servier; he had roles as consultant or advisor for Celgene, Merck. Matteo Fassan received research funding from Astellas Pharma. All the others authors declare no conflict of interest regarding the publication of this article.

Corresponding author: Matteo Fassan, MD, PhD, Associate Professor, Oncologist, Veneto Institute of Oncology IOV-IRCCS, via Gattamelata 64, Padua 35100, Italy. fotios.loupakis@iov.veneto.it

Telephone: +39-49-8215919 Fax: +39-49-8217929

Received: July 15, 2019
Peer-review started: July 16, 2019
First decision: August 2, 2019
Revised: August 26, 2019
Accepted: September 27, 2019
Article in press: September 27, 2019
Published online: October 14, 2019
Processing time: 90 Days and 13.8 Hours

Core Tip

Core tip: Gastric cancer (GC) still represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year. In the last decade, global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease, resulting in innovative molecular classifications of GC based on gene expression profiling and in the identification of new specific and sensitive predictive and prognostic biomarkers. At the same time, the development of targeted therapies has expanded the treatment scenario for advanced GC. The aim of the present manuscript is to provide a detailed and comprehensive overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC.